Faculty Profiles - MORI KAZUYUKI

Papers - MORI KAZUYUKI

Division display >> ／ All the affair displays1 - 45 of about 45

Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.

Mori K, Hatakeyama S, Enokida H, Miyake H, Kikuchi E, Nishiyama H, Ichikawa T, Kamai T, Kaji Y, Kume H, Kondo T, Matsuyama H, Masumori N, Kawauchi A, Takenaka A, Uemura H, Eto M, Nonomura N, Fujii Y, Hinotsu S, Ohyama C.

Int J Urol 31 ( 3 ) 194 - 207 2024.3

Humoral response to SARS-CoV-2 mRNA vaccine on in ABO blood type incompatible kidney transplant recipients treated with low-dose rituximab.

Hamaya T, Hatakeyama S, Yoneyama T, Tobisawa Y, Kodama H, Fujita T, Murakami R, Mori K, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Saitoh H, Narumi S, Tomita H, Ohyama C.

Sci Rep 13 ( 1 ) 15098 2023.9

Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.

Okuyama Y, Hatakeyama S, Tabata R, Fujimori D, Kawashima Y, Tanaka T, Fujita N, Okamoto T, Mori K, Yamamoto H, Yoneyama T, Hashimoto Y, Matsuoka T, Sato S, Ohyama C.

Int J Urol 30 ( 8 ) 649 - 657 2023.8

Altered gut microbiome associated with overactive bladder and daily urinary urgency.

Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

World J Urol 39 ( 3 ) 847 - 853 2021.3

N-glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas.

Kodama H, Yoneyama T, Tanaka T, Noro D, Tobisawa Y, Yamamoto H, Suto S, Hatakeyama S, Mori K, Yoneyama T, Hashimoto Y, Kakizaki I, Nakaji S, Ohyama C.

Cancer Med 10 ( 4 ) 1297 - 1313 2021.2

The association between serum serotonin levels and overactive bladder: results from a community-based cross-sectional study in Japan.

Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

World J Urol 39 ( 1 ) 169 - 175 2021.1

The association between gut microbiome and erectile dysfunction: a community- based cross-sectional study in Japan.

Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

Int Urol Nephrol 52 ( 8 ) 1421 - 1428 2020.8

The association between gut microbiome and erectile dysfunction: a community-based cross-sectional study in Japan.

Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

Int Urol Nephrol 2020.3

The association between serum serotonin levels and overactive bladder: results from a community-based cross-sectional study in Japan.

Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

World J Urol 2020.3

Influence of pretreatment quality of life on prognosis in patients with urothelial carcinoma.

Suppanuntaroek S, Hatakeyama S, Fujita N, Kubota Y, Suzuki Y, Okamoto T, Tobisawa Y, Yoneyama T, Yamamoto H, Mori K, Imai A, Yoneyama T, Hashimoto Y, Ohyama C.

Int J Clin Oncol. 25 ( 2 ) 362 - 369 2020.3

The Relationship Between Gait Function and Erectile Dysfunction: Results from a Community-Based Cross-Sectional Study in Japan.

Okamoto T, Hatakeyama S, Imai A, Konishi S, Okita K, Yamamoto H, Tobisawa Y, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

J Sex Med. 16 ( 12 ) 1922 - 1929 2019.12

Clinical significance of the LacdiNAc-glycosylated prostate-specific antigen assay for prostate cancer detection.

Yoneyama T, Tobisawa Y, Kaneko T, Kaya T, Hatakeyama S, Mori K, Sutoh Yoneyama M, Okubo T, Mitsuzuka K, Duivenvoorden W, Pinthus JH, Hashimoto Y, Ito A, Koie T, Suda Y, Gardiner RA, Ohyama C.

Cancer Sci. 110 ( 8 ) 2573 - 2589 2019.8

KK47細胞BCG生菌耐性株に対するナノパーティクルBCGの直接効果と耐性株の遺伝子発現解析

盛　和行、米山　徹、小玉　寛健、日下　歩、細越　正吾、得居　範子、山本　勇人、今井　篤、畠山　真吾、米山　高弘、橋本　安弘、古家　琢也、大山　力

泌尿器外科 31 ( 4 ) 401 - 402 2018.4

Aberrant N-Glycosylation Profile of Serum Immunoglobulins is a Diagnostic Biomarker of Urothelial Carcinomas.

Tanaka T, Yoneyama T, Noro D, Imanishi K, Kojima Y, Hatakeyama S, Tobisawa Y, Mori K, Yamamoto H, Imai A, Yoneyama T, Hashimoto Y, Koie T, Tanaka M, Nishimura SI, Kurauchi S, Takahashi I, Ohyama C.

Int J Mol Sci. 18 ( 12 ) 2632 - 2644 2017.12

BCG関連新規薬物療法の開発

盛　和行

日本臨床 75 ( Suppl 7 ) 319 - 322 2017.10

Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant.

Noro D, Yoneyama T, Hatakeyama S, Tobisawa Y, Mori K, Hashimoto Y, Koie T, Tanaka M, Nishimura SI, Sasaki H, Saito M, Harada H, Chikaraishi T, Ishida H, Tanabe K, Satoh S, Ohyama C.

Int J Mol Sci. 18 ( 8 ) 1731 - 1747 2017.8

BCG生菌double耐性株に対するナノパーティクルBCGの直接効果

盛　和行, 米山　徹, 野呂　大輔, 成田　拓磨, 田中　壽和, 萩原　和久, 及川　真亮, 今井　篤, 畠山　真吾, 米山　高弘, 橋本　安弘, 古家　琢也, 大山　力

泌尿器外科 30 ( 4 ) 442 - 443 2017.4

糖鎖を標的にした前立腺癌バイオマーカーの開発と臨床応用

大山　力，米山　徹，飛澤　悠葵，石川　友一，畠山　真吾，古家　琢也，盛　和行

臨床病理 65 ( 2 ) 210 - 217 2017.2

Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer

Hagiwara K, Tobisawa Y, Kaya T, Kaneko T, Hatakeyama S, Mori K, Hashimoto Y, Koie T, Suda Y, Ohyama C, Yoneyama T

Int J Mol Sci 18 ( 2 ) 261 - 276 2017.1

Core 2 β-1, 6-N-acetylglucosaminyltransferase-1 expression in prostate biopsy specimen is an indicator of prostate cancer aggressiveness

Sato T, Yoneyama T, Tobisawa Y, Hatakeyama S, Yamamoto H, Kojima Y, Mikami J, Mori K, Hashimoto Y, Koie T, Ohyama C

Biochem Biophys Res Commun 2016.1

I-branching N-acetylglucosaminyltransferase regulates prostate cancer invasiveness by enhancing α5β1 integrin signaling

Mikami J, Tobisawa Y, Yoneyama T, Hatakeyama S, Mori K, Hashimoto Y, Koie T, Ohyama C, Fukuda M：

Cancer Sci 2015.12

Detection of Core2 β-1, 6-N-Acetylglucosaminyltransferase in Post-Digital Rectal Examination Urine Is a Reliable Indicator for Extracapsular Extension of Prostate Cancer

Kojima Y, Yoneyama T, Hatakeyama S, Mikami J, Sato T, Mori K, Hashimoto Y, Koie T, Ohyama C, Fukuda M, Tobisawa Y

PLoS One 2015.9

Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.

Koie T, Ohyama C, Hosogoe S, Yamamoto H, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y, Yoneyama T, Tobisawa Y, Mori K

Case Rep Urol 2015.6

Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.

Koie T, Ohyama C, Yoneyama T, Yamamoto H, Imai A, Hatakeyama S, Hashimoto Y, Yoneyama T, Tobisawa Y, Mori K

BMC Urol 15 ( 1 ) 32 2015.4

Nanoparticle BCG

Kazuyuki Mori

Jpn J Urol Surg 28 ( 2 ) 151 - 154 2015.2

Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer.（共著）

Yoneyama T, Ohyama C, Hatakeyama S, Narita S, Habuchi T, Koie T, Mori K, Hidari KI, Yamaguchi M, Suzuki T, Tobisawa Y

Biochem Biophys Res Commun 448 ( 4 ) 390 - 396 2014.6

Outcome Comparison of ABO-Incompatible Kidney Transplantation WithLow-DoseRituximab andABO-CompatibleKidneyTransplantation:A Single-Center Experience.（共著）

1. Hatakeyama S, Fujita T, Murakami R, Suzuki Y, Sugiyama N, Yamamoto H, Okamoto A, Imai A, Tobisawa Y, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Koie T, Narumi S, Ohyama C

Transplantation Proceedings 46 ( 2 ) 445 - 448 2014.3

Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity.（共著）

Okamoto T, Yoneyama MS, Hatakeyama S, Mori K, Yamamoto H, Koie T, Saitoh H, Yamaya K, Funyu T, Fukuda M, Ohyama C, Tsuboi S.

Mol Med Rep 7 ( 2 ) 359 - 64 2013.2

Kidney Transplantation at Hirosaki kidney transplant unit-initial 5year experience.（共著）

Narumi S, Murakami R, Hatakeyama S, Fujita T, Koie T, Yoneyama T, Kudoh S, Ksmimura N, Mori K, Shimada M, Nakamura N, Umehara M, Saitoh H, Okumura K, Hakamada K, Ohyama C

Hirosaki Medical Journal 63 ( 2-4 ) 136 - 142 2012.12

MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis. （共著）

Suzuki Y, Sutoh M, Hatakeyama S, Mori K, Yamamoto H, Koie T, Saitoh H, Yamaya K, Funyu T, Habuchi T, Arai Y, Fukuda M, Ohyama C, Tsuboi S.

Int J Oncol 40 ( 6 ) 1831 - 1838 2012.7

A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans （共著）

Tsuboi S, Sutoh M, Hatakeyama S, Hiraoka N, Habuchi T, Horikawa Y, Hashimoto Y, Yoneyama T, Mori K, Koie T, Nakamura T, Saitoh H, Yamaya K, Funyu T, Fukuda M, Ohyama C.

EMBO J 30 ( 15 ) 3173 - 3185 2011.7

膀胱癌における尿テロメラーゼ活性簡易測定法の有用性

岩渕　郁哉, 盛　和行他

泌尿器科紀要 56 ( 10 ) 551 - 557 2010.10

Role of peroxynitrite and recombinant human manganese superoxide dismutase in reducing ischemia-reperfusion renal tissue injury

Rahman NA, Mori K, Mizukami M, Suzuki T, Takahashi N, Ohyama C

Transplantation Proceedings 41 3603 - 3610 2009.11

Protein profiling of post-prostatic massage urine specimens by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between prostate cancer and benign lesions.（共著）

Okamoto A, Yamamoto H, Imai A, Hatakeyama S, Iwabuchi I, Yoneyama T, Hashimoto Y, Koie T, Kamimura N, Mori K, Yamaya K, Ohyama C.

Oncol Rep 21 ( 1 ) 73 - 79 2009.1

Low-dose instillation therapy with bacille Calmette-Guérin Tokyo 172 strain after transurethral resection: historical cohort study（共著）

Yoneyama T, Ohyama C, Imai A, Ishimura H, Hagisawa S, Iwabuchi I, Mori K, Kamimura N, Koie T, Yamato T, Suzuki T.

Urology 71 ( 6 ) 1161 - 1165 2008.6

Short-term outcome of neoadjuvant gemcitabine-carboplatin therapy for muscle-invasive bladder cancer"jointly worked"

Yamato T, Okamoto A, Imai A, Ishimura D, Hatakeyama S, Hagisawa S, Iwabuchi I, Yoneyama T, Mori K, Koie T, Ohyama C.

Gan To Kagaku Ryoho 35 ( 1 ) 83 - 86 2008.1

前立腺癌—基礎・臨床研究のアップデートーII.臨床研究　診断　病期診断　臨床病期分類（共著）

大山　力,古家　琢也,盛　和行

日本臨床 65 ( Suppl10 ) 285 - 288 2007.12

INVESTIGATION OF ACTIVE BACILLUS CALMETTE-GUÉRIN (BCG) COMPONENT ON BLADDER CANCER CELL LINE(jointly worked)

Yoshikawa K et al

Hirosaki Med J 59 ( 1 ) 41 - 48 2007.11

被膜下前立腺摘除術（共著）

大山　力,大和　隆,米山　高弘,古家　琢也,盛　和行

臨床泌尿器科 61 ( 11 ) 883 - 888 2007.10

尿路として利用された腸管の発癌性について（共著）

大山　力,米山　高弘,神村　典孝,大和　隆,古家　琢也,萩沢　茂,岩渕　郁哉,盛　和行

Urology View 5 ( 3 ) 86 - 91 2007.6

Anti-tumor effects by nano particulate BCG(jointly worked)

Mori K et al

Ann Soc BCG BRM Immunother 30 ( 1 ) 71 - 77 2006.12

Anti-tumor effects of subcellular frctions from Mycobacterium bovis BCG Tokyo 172 and M. phlei(jointly worked)

Mori K et al

Ann Soc BCG BRM Immunother 29 ( 1 ) 59 - 68 2005.12

Direct anti-tumor effects of subcellular components of BCG-preliminary study on the particle size of effective component-(jointly worked)

Mori K et al

Ann Soc BCG BRM Immunother 28 ( 1 ) 37 - 42 2004.12

Expression of nitric oxide and inducible nitric oxide synthase in acute renal allograft rejection in the rat（共著）

A Suzuki, S Kudoh, K Mori, N Takahashi, T Suzuki

Int J Urol 11 ( 10 ) 833 - 844 2004.10

Anti-tumor effects of cell wall component fractionated from BCG(jointly worked)

Mori K et al

Ann Soc BCG BRM Immunother 27 ( 1 ) 33 - 41 2003.12

　PREV-NEXT　

1